Reversible posterior leukoencephalopathy syndrome induced by axitinib.

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinicoradiological syndrome that might be caused by anti-vascular endothelial growth factor (VEGF)-targeted compounds such as bevacizumab, sunitinib, and sorafenib. We report herein the first case of RPLS induced by axitinib, a multi-VEGF receptor tyrosine kinase inhibitor, with antiangiogenic… (More)
DOI: 10.1016/j.clgc.2013.08.008

1 Figure or Table

Topics

  • Presentations referencing similar topics